Immunovant, Inc. (IMVT) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $32.88: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.49; Below-average business quality.
Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor targeting IgG-mediated autoimmune diseases, with potentially registrational trials underway in Graves' disease, myasthenia gravis, CIDP, D2T RA, and a proof-of-concept trial in cutaneous... Read more
Sell if holding. Engine safety override at $32.88: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.49; Below-average business quality. Chart setup: RSI 44 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 60d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-12Recent Developments — Immunovant, Inc.
Latest news
- NEWS CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga May 26, 2026 positive
- NEWS Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62 — benzinga May 26, 2026 positive
- NEWS Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30 — benzinga May 22, 2026 positive
- NEWS These Analysts Increase Their Forecasts On Immunovant After Q4 Results — benzinga May 21, 2026 positive
- NEWS B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43 — benzinga May 21, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $32.88: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.49; Below-average business quality. Chart setup: RSI 44 mid-range, Bollinger mid-band. Prior stop was $30.58. Score 5.1/10, moderate confidence.
Take-profit target: $41.19 (+25.3% upside). Prior stop was $30.58. Stop-loss: $30.58.
Quality below floor (1.6 < 4.0).
Immunovant, Inc. trades at a P/E of N/A (forward -12.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts cover IMVT with a consensus score of 4.1/5. Average price target: $46.
What does Immunovant, Inc. do?Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor targeting IgG-mediated...
Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor targeting IgG-mediated autoimmune diseases, with potentially registrational trials underway in Graves' disease, myasthenia gravis, CIDP, D2T RA, and a proof-of-concept trial in cutaneous lupus. The company has no approved products and funds operations primarily through equity. First top-line data from registrational studies is not expected until 2027.